From Our Files Acarbose: Bayer has gained world first approval in Switzerland to market its hypoglycaemic

Pharmacology (continued)

Lower triglycerides production during carbohydrate-rich diets through acarbose, a glucoside hydrolase inhibitor. Nestel PJ, et al. Diabete and Metabolisme t1: 316, 1985

a-Glucosidase inhibitor acarbose: Fate and effects in man. Hagel J, et al. Gastroenterology 88: 1410, 1985

Alpha-glucosidase inhibitor in obesity. William-Oisson T. Acta Medica Scandinavica. Suppl. 706, 1986

Influence of acarbose and maltose on the react1vity of individual tryptophanyl residues 1n glucoamylase from aspergillus niger.

Svensson B, et al. Carlsberg Research Commumcations 51: 61, 1986 Long-term effect of acarbose on diurnal serum triglyceride. glucose.

insulin and adipose tissue lipoprotein lipase levels in patients with primary endogenous hypertriglyceridaemia, with or without type II

diabetes. Noyon R, et al. Netherlands Journal of Medicine 29: 157· 164, 1986

The effects of sucrose meal on insulin requirement in IDDM and its modulation by acarbose. Lecavalier L, et al. Diabete and

Metabolisme t2: 156·161, 1986 Effect of acarbose on carbohydrate tolerance during administration of a

fibre-free formula diet on healthy subjects. Walter-Sack IE, et al.

European Journal of Clinical Pharmacology 30: 607, 1986 Effect of an alpha-glycosidase inhibitor acarbose (BAY g 541) on diurnal

glucose metabolic variations. Vettor R, et al. Clinical Trials Journal

23: 161, 1986 Effects of acarbose in rats are influenced by the type of dietary starch

Glick Z, et al. Pharmacology Biochemistry and Behavior 25: 491,

1986 Effects of acarbose on the relationship between changes 1n GIP and

insulin responses to meals in normal subjects. Groop P-H, et al. Acta Endocrinologica 112: 361, 1986

Metabolic effects of acarbose in normal and diabetic rats: Long- and short-term administration. Hess ME, et al. Archives lnternationales de Pharmacodynamie et de Therapie 283: 163. 1986

Therapeutic use

Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucoside-hydrolase inhibitor. Walton RJ, et al. British Medical Journal 1· 220, 1979

Combined use of guar and acarbose in reduction of postprandial glycaemia. Jenkins DJA, et al. Lancet 2: 924, 1979

Effect of the a-glucosidase-inhibitor BAY -g-5421 on blood glucose control

of sulphonylurea-treated diabetics and insulin-treated diabetics. Sachse G, Willms B. Diabetologia 17 287, 1979

Treatment of non-Insulin dependent diabetic adults with a new glycoside hydrolase inhibitor (Bay g 5421) Sailer D. Roder G. Arzneimittel· Forschung 30 2182. 1980

Clinical application of a glucoside-hydrolase inhibitor (Bay g 5421) to patients with hyperlipidemia and maturity-onset type diabetes

mellitus Maruhama Y, Goto Y Tohoku Journal of Experimental Med1cine 130: 243, 1980

Effect of glucosidase inhibitor. Bay g 5421 (Acarbose), on the blood

glucose in obese diabetic patients type 2 (NIDDM). Laube H. et al. Arzne1mittei-Forschung 30: 1154, 1980

Long-term treatment of sulphonylurea-treated diabetiCS with the a· glucosidase inhibitor Bay g 5421 (Acarbose). Vierhapper H, et al. D1abetologia 20: 586, 1981

Acarbose as a therapeutic alternative in insulin allergy. Kolb S, Sailer D. Deutsche Medizinische Wochenschrift 106: 1085, 1981

Improvement of metabolic control in insulin dependent diabetics treated with the a-glucosidase inhibitor acarbose for two months. Gerard J, et al. Diabetologia 21. 446, 1981

Effect of a long-term acarbose therapy on the metabolic control of sulphonylurea-treated diabetic patients. Sachse G, et al. Diabetologia 22 221, 1982

0156·2703j87/0404-0023/0$01.00/0 © ADIS Press

Long-term treatment of diabetes with acarbose, a glucosidase inhibitor: efficacy, tolerability and effect of gastrointestinal hormones.

Hillebrand I. et al. Diabetologia 23: 468, 1982 Insulin level profiles with respect to glucobay treatment. Thonelt K. Die

Medizinische Welt 33: 1695, 1982 The pharmacology and clinical utilization of acarbose, a new oral

antidiabetic- conclusions. Otto H. D1e Medizinische Welt 33: 1699,

1982 Results of international glucobay studies. Hillebrand I. Die Medizimsche

Welt 33 1658, 1982 Glucobay and geriatrics Grossalbenhausen B. Die Medizinische Welt 33:

1662, 1982 Glucobay study at the bobingen-mumc1pal-hospital with long-term HbA1c

monitoring. Krepp HP. Die Medizinische Welt 33: 1677, 1982 General profiles and dietetic regimen of diabetics treated with acarbose.

Haydn G. Die Medizinische Welt 33 1674, 1982

Glucobay and dietetic-regimen studies at the Medizinische-Poliklimk-Der­Umversitat (Wurzburg). Gross W, et al. Die Medizinische Welt 33

1668. 1982 Results of a 3-month multicentric study of acarbose treatment in medical

practice. Schumann F. Die Medizinsiche Welt 33: 1686, 1982

Clinical profiles of diabetic patients. Schaefer HF. Die Medizinische Welt 33: 1659, 1982

Effect of glucobay on serum HbA 1 concentrations as determined in medical practice. Hoffmann J. Die Medizinische Welt 33: 1684, 1982

Partial results of a multicentric glucobay study, with longterm HbA1c monitoring at the Krankenhaus-Vinzentium (Ruhpolding, West Germany). Mechlem H, Thiel W. Die Medizinische Welt 33 1681,

1982 Acarbose studies with respect to in-patient (clinically controlled, at least

18 days) and out-patient (long-term) conditions Ravens KG, et al.

Die Medizinische Welt 33: 1670, 1982 Long-term glucobay treatment monitored in private practice. Bouzo H.

Die Medizinische Welt 33 1689, 1982 Long-term glucobay treatment monitored in private practice. Bouzo H

Die Medizinische Welt 33 1689. 1982 Self-monitoring of blood sugar levels by Insulin-dependent diabetics.

Doderlein W Die Mediz1nische Welt 33: 1697, 1982 Comparat1ve effectiveness of various glucobay dosages. Kiral A, Moeller

J. Die Medizinische Welt 33: 1693, 1982 3 1/2-year study of glucobay in medical practice. Englert R. Die

Medizinische Welt 33: 1609, 1982 Acarbose studies at the Klinik·Am-Frauenberg (Bad-Mergentheim West

Germany). Bergis K, et al. Die Medizinische Welt 33: 1665, 1982

A study of efficacy and tolerance of acarbose. Vargas R, et al. Clinical Pharmacology and Therapeutics 33: 216, 1983

Acarbose (BAY-g-5421) promotes weight loss in obese type II diabetics. Kamrath RO. et al. Clinical Research 31· 56A, 1983

Blood glucose concentrations and glycosuria during and after one year of acarbose therapy. Aubell R, et al. Arzneimittei-Forschung 33: 1314,

1983 Acarbose in react1ve hypoglycemia: a double-blind study. Gerard J, et al.

International Journal of Climcal Pharmacology, Therapy and

TOXICOlogy 22: 25, 1984 Acarbose treatment of non-insulin-dependent diabetes mellitus. Lardinois

CK, et al. Arch1ves of Internal Medic1ne 144: 345. 1984

Acarbose (Bay-g-5421) 1n the treatment of insulin-dependent diabetics.

Jelen B. Greenway FL Clinical Research 32 49A, 1984 Treatment of poorly controlled non-insulin-dependent diabetic patients

with acarbose. Scott RS, et al. Australian and New Zealand Journal of Medic1ne 14: 649, 1984

Acarbose treatment of sulfonylurea-treated non-Insulin-dependent

diabetics. Johansen K. D1abetes and Metabolisme 10 219, 1984 Comparison of acarbose and phenformin treatment in glibenclamide­

treated non-insulin dependent diabetics. Pagano G. et al Current

Therapeutic Research 39 143, 1986 Acarbose. Glucobay. Information update. Anon. Drugs of the Future 11:

795, 1986

INPHARIIIA~ 4 April 1987 23